Salesforce (CRM) Expands AI Collaboration With CVS Health Aetna Platform

CVS Health (NYSE: CVS) has broadened its AI-focused collaboration with Salesforce (NYSE: CRM) as part of a wider push to deliver more personalised digital tools to members and healthcare providers, according to a CVS Health announcement. The expanded partnership arrives alongside CVS's launch of Aetna Mental Health On Demand and updated GLP-1 formulary options, positioning Salesforce's platform at the centre of a multi-pronged digital health initiative. Shares of Salesforce last traded at $187.19 on Friday, May 29, up $11.02 on the session.

Expanded CVS Health Collaboration — What Changed

• CVS Health has broadened its existing AI-focused collaboration with Salesforce to support members and providers through more tailored digital tools, per the CVS announcement.
• The expanded work is part of CVS's launch of Aetna Mental Health On Demand, a new virtual behavioral health service designed to widen access to mental health care.
• CVS is simultaneously updating its pharmacy benefits with revised GLP-1 formulary options for weight-loss medications, with Salesforce's platform supporting the broader member-engagement infrastructure.
• The collaboration signals a deepening of Salesforce's role within the managed-care and pharmacy benefits ecosystem, according to the CVS announcement.

Why It Matters

The CVS expansion reflects a broader enterprise trend identified by Wedbush analysts, who argue that the contest for AI supremacy is shifting away from foundation models and toward the data infrastructure beneath them — the layer where Salesforce has long operated. Enterprises with decades of proprietary customer and member data are now positioned to extract the greatest value from AI, according to Wedbush, and a healthcare partnership of this scope puts Salesforce's platform directly in that role for one of the largest managed-care organisations in the United States. Salesforce is also among the practitioners named in the newly launched EC-Council ADG AI Framework, a governance model designed to help organisations secure and govern AI at scale in alignment with the EU AI Act, ISO/IEC 42001, and the NIST AI framework.

Taken together, the CVS collaboration and the ADG Framework participation underscore Salesforce's push to embed its AI capabilities across regulated, data-intensive industries where governance and trust carry particular weight. Both developments suggest the company is actively expanding its footprint in sectors — healthcare and financial services — where compliance requirements can serve as a competitive moat.

Wall Street View

Wall Street remains broadly constructive on Salesforce heading into this news. As of May 1, 2026, the consensus stood at 13 Strong Buy, 31 Buy, 13 Hold, and just one Strong Sell, with no Sell ratings recorded — a distribution largely unchanged from the prior month. Forward valuation sits at 12.1x (TTM — may not reflect latest quarter), a meaningful discount to the trailing multiple, suggesting analysts expect earnings growth to continue.

Investor Takeaway

The broadened CVS Health collaboration adds a high-profile healthcare anchor to Salesforce's AI partnership portfolio, with the platform now supporting virtual mental health services and pharmacy benefits management for Aetna members. Combined with Salesforce's involvement in the EC-Council's enterprise AI governance framework, the company appears to be building credibility in compliance-sensitive verticals that could support durable, long-term contract relationships. With a near-unanimous Buy-side consensus and no Sell ratings among covering analysts, the street appears to view these incremental partnership wins as consistent with the company's existing growth trajectory.